These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 9716580

  • 1. A randomized phase-II study of BB-10010 (macrophage inflammatory protein- 1alpha) in patients with advanced breast cancer receiving 5-fluorouracil, adriamycin, and cyclophosphamide chemotherapy.
    Clemons MJ, Marshall E, Dürig J, Watanabe K, Howell A, Miles D, Earl H, Kiernan J, Griffiths A, Towlson K, DeTakats P, Testa NG, Dougal M, Hunter MG, Wood LM, Czaplewski LG, Millar A, Dexter TM, Lord BI.
    Blood; 1998 Sep 01; 92(5):1532-40. PubMed ID: 9716580
    [Abstract] [Full Text] [Related]

  • 2. A randomized phase II study of BB-10010: a variant of human macrophage inflammatory protein-1alpha for patients receiving high-dose etoposide and cyclophosphamide for malignant lymphoma and breast cancer.
    Bernstein SH, Eaves CJ, Herzig R, Fay J, Lynch J, Phillips GL, Christiansen N, Reece D, Ericson S, Stephan M, Kovalsky M, Hawkins K, Rasmussen H, Devos A, Herzig GP.
    Br J Haematol; 1997 Dec 01; 99(4):888-95. PubMed ID: 9432038
    [Abstract] [Full Text] [Related]

  • 3. Mobilisation kinetics of primitive haemopoietic cells following G-CSF with or without chemotherapy for advanced breast cancer.
    Baumann I, Swindell R, Van Hoeff ME, Dexter TM, de Wynter E, Lange C, Luft T, Howell A, Testa NG.
    Ann Oncol; 1996 Dec 01; 7(10):1051-7. PubMed ID: 9037364
    [Abstract] [Full Text] [Related]

  • 4. A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients.
    O'Shaughnessy JA, Denicoff AM, Venzon DJ, Danforth D, Pierce LJ, Frame JN, Bastian A, Ghosh B, Goldspiel B, Miller L.
    Ann Oncol; 1994 Oct 01; 5(8):709-16. PubMed ID: 7826903
    [Abstract] [Full Text] [Related]

  • 5. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer.
    Jones SE, Schottstaedt MW, Duncan LA, Kirby RL, Good RH, Mennel RG, George TK, Snyder DA, Watkins DL, Denham CA, Hoyes FA, Rubin AS.
    J Clin Oncol; 1996 Nov 01; 14(11):2976-83. PubMed ID: 8918495
    [Abstract] [Full Text] [Related]

  • 6. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer.
    Elias AD, Ayash L, Anderson KC, Hunt M, Wheeler C, Schwartz G, Tepler I, Mazanet R, Lynch C, Pap S.
    Blood; 1992 Jun 01; 79(11):3036-44. PubMed ID: 1350229
    [Abstract] [Full Text] [Related]

  • 7. Post-5-fluorouracil human marrow: stem cell characteristics and renewal properties after autologous marrow transplantation.
    Stewart FM, Temeles D, Lowry P, Thraves T, Grosh WW, Quesenberry PJ.
    Blood; 1993 May 01; 81(9):2283-9. PubMed ID: 8481510
    [Abstract] [Full Text] [Related]

  • 8. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
    Morgan RJ, Doroshow JH, Venkataraman K, Chang K, Raschko J, Somlo G, Leong L, Tetef M, Shibata S, Hamasaki V, Margolin K, Forman S, Akman S, Coluzzi P, Ahn C, Weiss L, Gadgil U, Harrison J.
    Clin Cancer Res; 1997 Dec 01; 3(12 Pt 1):2337-45. PubMed ID: 9815632
    [Abstract] [Full Text] [Related]

  • 9. Randomized, double-blind, placebo-controlled trial to evaluate the hematopoietic growth factor PIXY321 after moderate-dose fluorouracil, doxorubicin, and cyclophosphamide in stage II and III breast cancer.
    Jones SE, Khandelwal P, McIntyre K, Mennel R, Orr D, Kirby R, Agura E, Duncan L, Hyman W, Roque T, Regan D, Schuster M, Dimitrov N, Garrison L, Lange M.
    J Clin Oncol; 1999 Oct 01; 17(10):3025-32. PubMed ID: 10506596
    [Abstract] [Full Text] [Related]

  • 10. Continuous infusion of macrophage inflammatory protein MIP-1alpha enhances leucocyte recovery and haemopoietic progenitor cell mobilization after cyclophosphamide.
    Marshall E, Woolford LB, Lord BI.
    Br J Cancer; 1997 Oct 01; 75(12):1715-20. PubMed ID: 9192972
    [Abstract] [Full Text] [Related]

  • 11. Clinical effects of human macrophage inflammatory protein-1 alpha MIP-1 alpha (LD78) administration to humans: a phase I study in cancer patients and normal healthy volunteers with the genetically engineered variant, BB-10010.
    Marshall E, Howell AH, Powles R, Hunter MG, Edwards M, Wood LM, Czaplewski L, Puttick R, Warrington S, Boyce M, Testa N, Dexter TM, Lord BI, Millar A.
    Eur J Cancer; 1998 Jun 01; 34(7):1023-9. PubMed ID: 9849450
    [Abstract] [Full Text] [Related]

  • 12. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
    de Graaf H, Mulder NH, Willemse PH, van der Graaf WT, Sleijfer DT, Zijlstra JG, Elias M, Sibinga CT, Vellenga E, de Vries EG.
    Anticancer Res; 1995 Jun 01; 15(6B):2851-6. PubMed ID: 8669878
    [Abstract] [Full Text] [Related]

  • 13. Dose-escalating induction chemotherapy supported by lenograstim preceding high-dose consolidation chemotherapy for advanced breast cancer. Selection of the most acceptable regimen to induce maximal tumor response and investigation of the optimal time to collect peripheral blood progenitor cells for haematological rescue after high-dose consolidation chemotherapy.
    Van Hoef ME, Baumann I, Lange C, Luft T, de Wynter EA, Ranson M, Morgenstern GR, Yvers A, Dexter TM, Testa NG.
    Ann Oncol; 1994 Mar 01; 5(3):217-24. PubMed ID: 7514434
    [Abstract] [Full Text] [Related]

  • 14. A phase I study of sequential versus concurrent interleukin-3 and granulocyte-macrophage colony-stimulating factor in advanced breast cancer patients treated with FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy.
    O'Shaughnessy JA, Venzon DJ, Gossard M, Noone MH, Denicoff A, Tolcher A, Danforth D, Jacobson J, Keegan P, Miller L, Chow C, Goldspiel B, Cowan KH.
    Blood; 1995 Oct 15; 86(8):2913-21. PubMed ID: 7579383
    [Abstract] [Full Text] [Related]

  • 15. Prospective, randomized trial of 5-fluorouracil, leucovorin, doxorubicin, and cyclophosphamide chemotherapy in combination with the interleukin-3/granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein (PIXY321) versus GM-CSF in patients with advanced breast cancer.
    O'Shaughnessy JA, Tolcher A, Riseberg D, Venzon D, Zujewski J, Noone M, Gossard M, Danforth D, Jacobson J, Chang V, Goldspiel B, Keegan P, Giusti R, Cowan KH.
    Blood; 1996 Mar 15; 87(6):2205-11. PubMed ID: 8630380
    [Abstract] [Full Text] [Related]

  • 16. Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony-stimulating factor. A randomized trial.
    Kritz A, Crown JP, Motzer RJ, Reich LM, Heller G, Moore MP, Hamilton N, Yao TJ, Heelan RT, Schneider JG.
    Cancer; 1993 Apr 15; 71(8):2515-21. PubMed ID: 8095854
    [Abstract] [Full Text] [Related]

  • 17. Myeloid progenitor cell proliferation and mobilization effects of BB10010, a genetically engineered variant of human macrophage inflammatory protein-1alpha, in a phase I clinical trial in patients with relapsed/refractory breast cancer.
    Broxmeyer HE, Orazi A, Hague NL, Sledge GW, Rasmussen H, Gordon MS.
    Blood Cells Mol Dis; 1998 Mar 15; 24(1):14-30. PubMed ID: 9516378
    [Abstract] [Full Text] [Related]

  • 18. The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program.
    Elias AD, Ibrahim J, Richardson P, Avigan D, Joyce R, Reich E, McCauley M, Wheeler C, Frei E.
    Biol Blood Marrow Transplant; 2002 Mar 15; 8(4):198-205. PubMed ID: 12017145
    [Abstract] [Full Text] [Related]

  • 19. Thrombopoietin and chemokine mRNA expression in patient post-chemotherapy and in vitro cytokine-treated marrow stromal cell layers.
    Schwartz GN, Kammula U, Warren MK, Park MK, Yan XY, Marincola FM, Gress RE.
    Stem Cells; 2000 Mar 15; 18(5):331-42. PubMed ID: 11007917
    [Abstract] [Full Text] [Related]

  • 20. Protective effects of BB-10010 treatment on chemotherapy-induced neutropenia in mice.
    Gilmore GL, DePasquale DK, Shadduck RK.
    Exp Hematol; 1999 Feb 15; 27(2):195-202. PubMed ID: 10029156
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.